论文部分内容阅读
目的对131I和抗甲状腺药物(ATD)治疗男性甲状腺功能亢进症(以下简称甲亢)合并低钾周期性瘫痪进行疗效比较,评价两种方法的优劣。方法将40例男性甲亢患者随机分为两组各20例,分别应用131I和ATD两种方法治疗,随访5年,详细记录治疗效果及其不良反应。结果 131I治疗组20例治愈率95%,复发率5%;ATD治疗组治愈率45%,复发率55%。永久性甲状腺功能低下发生率131I与ATD分别为20%和0。131I组未出现肝功能受损,发生白细胞降低1例;ATD组出现肝功能受损2例,白细胞降低4例。结论 131I治疗男性甲亢并低钾性周期性瘫痪疗效优于ATD,尽管有甲状腺功能低下发生,但甲亢复发及出现其他系统损伤较ATD治疗少。
Objective To compare the efficacy of 131I and antithyroid drugs (ATD) in the treatment of male hypothyroidism (hereinafter referred to as hyperthyroidism) with hypokalemic periodic paralysis, and to evaluate the advantages and disadvantages of the two methods. Methods Forty male patients with hyperthyroidism were randomly divided into two groups of 20 cases. The patients were treated with 131I and ATD respectively. The patients were followed up for 5 years. The treatment effect and adverse reactions were recorded in detail. Results The cure rate was 95% and the recurrence rate was 20% in 20 cases of 131I treatment group. The cure rate was 45% and the recurrence rate was 55% in ATD treatment group. The incidence of permanent hypothyroidism in 131I and ATD were 20% and 0.131I, respectively. No hepatic impairment occurred in 1 case, leukopenia occurred in 1 case. In ATD group, 2 cases of liver dysfunction and 4 cases of leukopenia were found. Conclusion 131I treatment of male patients with hypokalemia and hypokalemic periodic paralysis better than ATD, despite the occurrence of hypothyroidism, but the recurrence of hyperthyroidism and other systemic injury than ATD treatment less.